

HIGH RESOLUTION LC-MS/MS SCREENING FOR SECONDARY METABOLITES IN BULGARIAN SPECIES OF GENUS *Astragalus* L.Aleksandar M. Shkondrov^a and Ilina N. Krasteva^{a,*}^aDepartment of Pharmacognosy, Faculty of Pharmacy, Medical University of Sofia, Sofia, Bulgaria

Recebido em 01/09/2020; aceito em 08/02/2021; publicado na web em 26/02/2021

The phytochemical content of some *Astragalus* species distributed in Bulgarian flora has been previously studied. Among other compounds, flavoalkaloids, acylated flavonoids, flavonoid triglycosides and cycloartane saponins have been isolated so far. The composition of the rest of the representatives of this genus in Bulgaria is not explored yet. The aim of this study was to perform a screening for the presence of selected rare secondary metabolites (flavoalkaloids, acylated flavonoids, flavonoid triglycosides and cycloartane saponins) in selected *Astragalus* species. Samples were collected in different phenological stages and from different locations in the country. A novel and rapid ultra-high performance liquid chromatography – high resolution electrospray ionisation mass spectrometry (UHPLC-HRESIMS) method was developed and applied. For the first time a flavoalkaloid glycoside was determined from extracts of *A. onobrychis* var. *chlorocarpus* and *A. glycyphylloides*. From *A. depressus* an acylated derivative of kaempferol was newly identified. The flavonol triglycosides camelliaside A, alcesefoliside and mauritianin were proved in samples of *A. glycyphylloides*, *A. onobrychis* var. *chlorocarpus* and *A. cicer* for the first time as well.

Keywords: *Astragalus* species; flavoalkaloids; flavonoids; saponins; qualitative analysis; UHPLC-HRESIMS.

INTRODUCTION

Genus *Astragalus* L. (Fabaceae) is comprised of more than 3500 species, distributed in every continent except Antarctica.¹ In Europe the genus is presented with 135 species, 31 of which are distributed in Bulgaria.^{2,3} The plants have been known to accumulate mainly three groups of pharmacologically active compounds – polysaccharides, flavonoids and saponins.⁴

Recently, *N*-(8-methylquercetin-3-*O*-[α -L-rhamnopyranosyl-(1 \rightarrow 2)-[α -L-rhamnopyranosyl-(1 \rightarrow 6)]- β -D-galactopyranosyl])-3-hydroxypiperidin-2-one and *N*-(8-methylkaempferol-3-*O*-[α -L-rhamnopyranosyl-(1 \rightarrow 2)-[α -L-rhamnopyranosyl-(1 \rightarrow 6)]- β -D-galactopyranosyl])-3-hydroxypiperidin-2-one were isolated from *A. monspessulanus* subsp. *monspessulanus*.⁵ Flavoalkaloids are a rare group of plant secondary metabolites, known previously only as aglycones.⁶ This leads to a further investigation of possible accumulation of flavoalkaloids in other representatives of the genus.

Long considered a chemotaxonomical marker of genera *Rosa* and *Plathyodon* (Rosaceae), flavonoids acylated with 3-hydroxy-3-methylglutaric acid were also isolated from *Astragalus* species.⁷⁻⁹ Quercetin-3-*O*- α -L-rhamnopyranosyl-(1 \rightarrow 2)-[6-*O*-(3-hydroxy-3-methylglutaryl)- β -D-galactopyranoside and kaempferol-3-*O*- α -L-rhamnopyranosyl-(1 \rightarrow 2)-[6-*O*-(3-hydroxy-3-methylglutaryl)- β -D-galactopyranoside were obtained from the overground parts of *A. monspessulanus* subsp. *illyricus*.⁵ This presents a new opportunity to establish the chemotaxonomical significance of these acylated flavonoids for the genus.

Flavonoid triglycosides occur quite rarely and their biosynthesis is undoubtedly a result of interconnecting pathways.¹⁰ Quercetin-3-*O*- α -L-rhamnopyranosyl-(1 \rightarrow 2)-[α -L-rhamnopyranosyl-(1 \rightarrow 6)]- β -D-galactopyranoside (alcesefoliside) and kaempferol-3-*O*- α -L-rhamnopyranosyl-(1 \rightarrow 2)-[α -L-rhamnopyranosyl-(1 \rightarrow 6)]- β -D-galactopyranoside (mauritianin) were isolated from the aerial parts of *A. monspessulanus* subsp. *monspessulanus*.⁵

Kaempferol-3-*O*-[2-*O*- β -D-galactopyranosyl-6-*O*- α -L-rhamnopyranosyl]- β -D-glucopyranoside (camelliaside A) was isolated from the herbs of *A. glycyphyllos*.¹¹

Studies of Bulgarian *Astragalus* species showed that they have an intermediate content – some contain pentacyclic triterpenoid saponins, while in other species the accumulation of cycloartane saponins was proved.^{12,13} Previously, 17(*R*),20(*R*)-3 β ,6 α ,16 β -trihydroxycycloartanyl-23-carboxylic acid 16-lactone 3-*O*- β -D-glucopyranoside was isolated from the herbs of *A. glycyphyllos*.¹¹ From a taxonomical point of view the saponin content of other species is of particular interest.¹⁴

The aim of this study was to conduct an UHPLC-HRESIMS screening for the presence of selected rare secondary metabolites in species of genus *Astragalus* occurring in Bulgaria

EXPERIMENTAL**Plant material**

The overground parts of seven *Astragalus* species (Table 1) were collected either in flowering or in fructification, from marked plants and/or from different localities in Bulgaria. The species were identified by Dr. D. Pavlova from Faculty of Biology, Sofia University, Bulgaria and two of us (A. S. and I. K.). Voucher specimens were deposited in the Herbarium of the Sofia University (SO) or at the Herbarium of the Institute of Biodiversity and Ecosystem Research at the Bulgarian Academy of Sciences (SOM).

Extraction

Overground parts were dried at room temperature and then individually reduced to a powder. A sample of each (200 mg) was refluxed twice with 3 mL 80% MeOH on a boiling water bath (100 °C) for 30 min each. The extracts obtained were filtered, combined in a volumetric flask and the volume adjusted to 10.0 mL with the same solvent. An aliquot of 2 μ L was injected to UHPLC.

*e-mail: krasteva.ilina@abv.bg

Table 1. Samples of Bulgarian *Astragalus* species

Sample No.	Overground parts of	Year	Locality; coordinates	Voucher specimen	Phenological stage
1	<i>A. cicer</i>	2013	Sofia; 42°41'52"N, 23°19'19"E	SO 102681	flowering
2	<i>A. cicer</i>	2016	Sofia; 42°41'52"N, 23°19'19"E	SOM 1394	fructification
3	<i>A. depressus</i>	2015	Erma; 42°48'45"N, 22°34'52"E	SOM 1402	flowering
4	<i>A. glycyphylloides</i>	2018	Vitosha; 42°33'36"N, 23°16'48"E	SO 093817	flowering
5	<i>A. glycyphyllos</i>	2019	Rila; 42°7'40"N, 23°7'56"E	SO 107612	flowering
6	<i>A. glycyphyllos</i>	2012	Vitosha; 42°33'36"N, 23°16'48"E	SO 107613	flowering
7	<i>A. monspessulanus</i> subsp. <i>monspessulanus</i>	2016	Devin; 41°43'41"N, 24°26'59"E	SOM 1391	fructification
8	<i>A. monspessulanus</i> subsp. <i>monspessulanus</i>	2016	Slavianka; 41°33'57"N, 24°44'41"E	SOM 1392	flowering
9	<i>A. monspessulanus</i> subsp. <i>ilyricus</i>	2015	Erma; 42°48'45"N, 22°34'52"E	SO 107532	flowering
10	<i>A. onobrychis</i> var. <i>chlorocarpus</i>	2013	Stara Zagora; 42°23'37"N, 25°38'46"E	SO 107538	flowering
11	<i>A. onobrychis</i> var. <i>chlorocarpus</i>	2016	Golo Bardo; 42°35' 17"N, 23°3'2"E	SOM 1393	flowering
12	<i>A. onobrychis</i> var. <i>chlorocarpus</i>	2016	Vitosha; 42°33'36"N, 23°16'48"E	SOM 1390	flowering
13	<i>A. ponticus</i>	2013	Pleven; 43°24'32"N, 24°37'4"E	SO 107539	flowering

Ultra high performance liquid chromatography-high resolution electrospray ionization mass spectrometry (UHPLC-HRESIMS)

A Q Exactive™ Plus Orbitrap mass spectrometer with a heated electrospray ionisation (HESI) ion source (ThermoFisher Scientific, Bremen, Germany) coupled with a UHPLC system (Dionex UltiMate 3000 RSLC, ThermoFisher Scientific, Bremen, Germany) was used. The full scan MS was set at: resolution 70000 (at m/z 200), AGC target $3e^6$, max IT 100 ms, scan range 250 to 1700 m/z . The MS² conditions were: resolution 17500 (at m/z 200), AGC target $1e^5$, max IT 50 ms, mass range m/z 200 to 2000, isolation window 2.0 m/z and (N)CE 20. The ionization device (HESI source) was operating at: +3.5 or -2.5 kV spray voltage and 320 °C capillary and probe temperature, 38 arbitrary units (a.u., as set by the Extactive Tune software) of sheath gas and 12 a.u. of auxiliary gas (both Nitrogen); S-Lens RF level 50.0. UHPLC separations were performed using a Kromasil® C₁₈ column (1.9 µm, 2.1 x 50 mm, Akzo Nobel, Sweden) maintained at 40 °C; mobile phase H₂O added 0.1% HCOOH (A) and MeCN added 0.1% HCOOH (B) with a flow rate of 0.3 mL/min and gradient elution (10% B for 0.5 min, then increase to 30% B for 7 min, isocratic with 30% B for 1.5 min, increase to 95% B for 3.5 min, isocratic with 95% B for 2 min, then return to 10% B for 0.1 min).

Reference substances

The structures of the reference substances are shown in Figure 1 and the chemical names are given in Table 2. They were isolated from the plant source (purity more than 99 %, HPLC) and their structures were confirmed by extensive spectral analyses and comparison to data reported before.^{5,11} Rutin (99.8% purity) was purchased from Sigma Aldrich. Standard solutions of each reference substance were prepared in MeOH (100 ng mL). Two µL of each solution were injected in the UHPLC-HRESIMS system three times.

Detection

Detection of the compounds in the samples was based on the full scan chromatograms in both positive and negative mode, considering the retention time, compared to the standards. Identification was supported by MS² experiments which revealed the aglycone part of the molecule in question as well as the successive loss of monosaccharides of the sugar moiety. The fragmentation pattern was compared to that of the reference substance (Table 2). The following criteria were adopted for the identification: coincidence of both

the retention time and of the fragmentation pattern with that of the standard in both positive and negative modes.

Software

The software Xcalibur®, Version 4.2 (Thermo Scientific) was used to collect raw data and to process the results.

RESULTS AND DISCUSSION

Method development

Liquid chromatography coupled with mass spectrometry is considered to be one of the most accurate methods to identify multiple compounds in complex samples.¹⁵ A novel UHPLC-HRESIMS method was developed for determination of selected secondary metabolites in plant extracts. The method was rapid and efficient. As recommended by the The International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH) the validation was performed on several parameters.¹⁶ Specificity against each reference substance was examined on blank solutions. There were no peaks in the chromatogram of the blank solution with retention time (Rt) similar to any of the reference compounds (Table 2). The limit of detection, based on three times the signal-to-noise ratio, was calculated for each reference substance (Table 2) by injecting 2 µL of each standard solution three times. The repeatability (SD %) on six solutions containing rutin was ± 1.1%.

Rutin, as a well-known flavonoid was initially used to develop the method.¹⁰ An ion [M-H]⁻ (m/z 609.1470, C₂₇H₂₉O₁₆⁻) and in MS² ions with m/z 300.0280 (C₁₅H₈O₇⁻, [Que-H]⁻) and with m/z 301.0349 (C₁₅H₉O₇⁻, [Que-H]⁻) were observed, while in the positive mode a precursor ion [M+H]⁺ with m/z 611.1605 (C₂₇H₃₁O₁₆⁺) and in the MS² a corresponding ion with m/z 303.0496 (C₁₅H₁₁O₇⁺) for [Que+H]⁺ were registered.¹⁰ The flavonoid was identified in all extracts except those of *A. depressus* and *A. glycyphylloides* (Samples 3 and 4, Table 3). These findings are with accordance with previous results.^{4,17-19} Moreover, the results of rutin content and their coincidence with the literature prove the accuracy of the screening method presented.

Mass spectral analysis of reference substances

The mass fragmentation of the standards was investigated and the experimental findings are presented in Table 2. The principal fragmentation patterns of flavoalkaloids and flavonoids are shown on Figure 2, except for rutin, since its fragmentation was previously described.¹⁰ The fragmentation of ECAS is presented in Figure 3.




Figure 1. Reference substances used to perform the screening; abbreviations are given in Table 2

In the negative MS² spectrum of all flavonol glycosides described above, a fragment ion with m/z 151 ($C_7H_5O_4^-$) and in the positive MS² spectrum a fragment ion with m/z 153 ($C_7H_5O_4^+$), both due to retro-Diels-Alder (RDA) fragmentation of their aglycone ($^{1,3}A^-$ or $^{1,3}A^+$) were observed.²⁰ This was not registered for the flavoalkaloids investigated.

In the mass spectrum of **QueFA**, a deprotonated ion $[M-H]^-$ m/z 882.2692 ($C_{39}H_{48}NO_{22}^-$) with low abundance was observed. The fragmentation led to an ion with m/z 315.0505 ($C_{16}H_{11}O_7^-$), corresponding to deprotonated methylquercetin [methylQue-H]⁻ after cleavage of the hydroxypiperidine-2-one moiety.^{21–23} A protonated ion $[M+H]^+$ m/z 884.2809 ($C_{39}H_{50}NO_{22}^+$) and a fragment with m/z 317.0728 ($C_{16}H_{13}O_7^+$, [methylQue+H]⁺), were registered in the positive mode (see Figure 2 and Table 2).¹⁰ In the spectrum of **KaeFA**, no deprotonated molecular ion $[M-H]^-$ was observed (theoretically, m/z 866, $C_{39}H_{48}NO_{21}^-$), but a stable and abundant ion with m/z 901.2642, corresponding to $[M+Cl]^-$ ($C_{39}H_{48}NO_{21}Cl^-$) was found (Table 2). In the MS² spectrum of this adduct the most abundant was the $[M-H]^-$ ion (m/z 866.2718, $C_{39}H_{48}NO_{21}^-$). The aglycone – a deprotonated methylkaempferol [methylKae-H]⁻ with m/z 299.4627 ($C_{16}H_{11}O_6^-$, also formed after cleavage of the hydroxypiperidine-2-one moiety) was registered as well.²⁴ A precursor ion $[M+H]^+$ (m/z 868.2857, $C_{39}H_{50}NO_{21}^+$) was observed in positive ionization mode. Its fragmentation led to the formation of [methylKae+H]⁺ (m/z 301.0711, $C_{16}H_{13}O_6^+$) as shown in Figure 2 and Table 2).²⁴ A deprotonated molecular ion (m/z 753.1893, $C_{33}H_{37}O_{20}^-$) was observed in the spectrum of **QueHMG** and after cleavage of the 3-hydroxy-3-methylglutaric residue (HMG), an ion corresponding to deprotonated rutin (m/z 609.1462, $C_{27}H_{29}O_{16}^-$), a fragment ion with m/z 301.0347 ($C_{15}H_9O_7^-$) [Que-H]⁻, and an ion of the type $[M-(rha-gal-HMG)-H]^-$ (m/z 300.0278, $C_{15}H_8O_7^-$, most abundant in MS²) were registered.^{21–23} A precursor ion $[M+H]^+$ (m/z 755.2020, $C_{33}H_{39}O_{20}^+$) and an ion with m/z 303.0494 ($C_{15}H_{11}O_7^+$, [Que+H]⁺)

were observed in the positive polarity (see Figure 2 and Table 2).²¹ In the negative mode in the spectrum of **KaeHMG** an ion $[M-H]^-$ (m/z 737.1942, $C_{33}H_{37}O_{19}^-$), and an ion with m/z 593.1515 ($C_{27}H_{29}O_{15}^-$, after HMG cleavage) were recorded. Characteristic ions of the deprotonated aglycone (m/z 285.0398, $C_{15}H_9O_6^-$) and $[Kae-H]^-$ with m/z 284.0327 ($C_{15}H_8O_6^-$) were observed.^{10,22,23} In the positive mode, a precursor ion $[M+H]^+$ with m/z 739.2072 ($C_{39}H_{39}O_{19}^+$), an ion with m/z 595.1538 ($C_{27}H_{31}O_{15}^+$, [Kae-rha-gal+H]⁺, after HMG elimination), and a fragment ion with m/z 287.0545 ($C_{15}H_{11}O_6^+$, [Kae+H]⁺) were observed (see Figure 2 and Table 2).²⁴ In the spectrum of camelliaside A an ion $[M-H]^-$ (m/z 755.2035, $C_{33}H_{39}O_{20}^-$) was determined and. An ion of $[Kae-H]^-$, m/z 285.0399 ($C_{15}H_9O_6^-$) and $[Kae-H]^-$ with m/z 284.0328 ($C_{15}H_8O_6^-$) were detected.¹¹ A precursor ion $[M+H]^+$ with m/z 757.2191 ($C_{33}H_{41}O_{20}^+$) was observed in positive polarity, which gave a fragment ion for $[Kae+H]^+$ with m/z 287.0551, $C_{15}H_{11}O_6^+$ (see Figure 2 and Table 2).¹⁰ In the spectrum of alcesefoliside an ion $[M-H]^-$ was identified (m/z 755.2045, $C_{33}H_{39}O_{20}^-$).¹⁰ The ions $[Que-H]^-$ with m/z 300.0279 ($C_{15}H_8O_7^-$) and $[Que-H]^-$ with m/z 301.0328 ($C_{15}H_9O_7^-$) distinguished the compound from camelliaside A, which had similar retention time. A precursor ion $[M+H]^+$ (m/z 757.2191, $C_{33}H_{41}O_{20}^+$) was observed, as well as in MS² the aglycone with m/z 303.0499 ($C_{15}H_{11}O_7^+$, [Que+H]⁺) (see Figure 2 and Table 2).¹⁰ In the negative mode in the spectrum of mauritianin an ion $[M-H]^-$ was observed (m/z 739.2100, $C_{33}H_{39}O_{19}^-$) and in the MS² ions $[Kae-H]^-$ with m/z 284.0329 ($C_{15}H_8O_6^-$) and $[Kae-H]^-$ with m/z 285.0393 ($C_{15}H_9O_6^-$) were recorded.^{22–24} In the positive mode a precursor ion $[M+H]^+$ (m/z 741.2245, $C_{33}H_{41}O_{19}^+$), and in the MS² an ion with m/z 287.0549 ($C_{15}H_{11}O_6^+$), corresponding to $[Kae+H]^+$ were found (see Figure 2 and Table 2).²⁴

In the negative ionization mode, 17(*R*),20(*R*)-3 β ,6 α ,16 β -trihydroxycycloartanyl-23-carboxylic acid 16-lactone 3-*O*- β -D-glucopyranoside (ECAS) forms a formate adduct $[M-H-HCOOH]^-$ with

Table 2. Standard substances and analytical parameters used to identify secondary metabolites in the samples

Standard substance (abbreviation)	Rt ± SD, min	Exact mass; molecular formula	ESI (+) Precursor ion; MS ² (relative abundance in %)*	ESI (-) Precursor ion; MS ² (relative abundance in %)*	LOD ± SD, ng/mL
<i>N</i> -(8-methylquercetin-3- <i>O</i> -[α -L-rhamnopyranosyl-(1 \rightarrow 2)]-[α -L-rhamnopyranosyl-(1 \rightarrow 6)]- β -D-galactopyranosyl]-3-hydroxypiperidin-2-one (QueFA)	2.47 ± 0.015	883.2695; C ₃₉ H ₄₉ NO ₂₂	884.2809 C ₃₉ H ₅₀ NO ₂₂ ⁺ ; 771.2345 C ₃₄ H ₄₃ O ₂₀ ⁺ (28), 625.1763 C ₂₈ H ₃₃ O ₁₆ ⁺ (3), 479.1189 C ₂₂ H ₂₃ O ₁₂ ⁺ (12), 317.0728 C ₁₆ H ₁₃ O ₇ ⁺ (100)	882.2692 C ₃₉ H ₄₈ NO ₂₂ ⁻ ; 769.2191 C ₃₄ H ₄₁ O ₂₀ ⁻ (21), 623.1612 C ₂₈ H ₃₁ O ₁₆ ⁻ (8), 477.1033 C ₂₂ H ₂₁ O ₁₂ ⁻ (10), 315.0505 C ₁₆ H ₁₁ O ₇ ⁻ (100)	0.18 ± 0.01
<i>N</i> -(8-methylkaempferol-3- <i>O</i> -[α -L-rhamnopyranosyl-(1 \rightarrow 2)]-[α -L-rhamnopyranosyl-(1 \rightarrow 6)]- β -D-galactopyranosyl]-3-hydroxypiperidin-2-one (KaeFA)	3.00 ± 0.010	867.2747; C ₃₉ H ₄₉ NO ₂₁	868.2857 C ₃₉ H ₅₀ NO ₂₁ ⁺ ; 755.2399 C ₃₄ H ₄₃ O ₁₉ ⁺ (11), 609.1820 C ₂₈ H ₃₃ O ₁₅ ⁺ (6), 463.1075 C ₂₂ H ₂₃ O ₁₁ ⁺ (44), 301.0711 C ₁₆ H ₁₃ O ₆ ⁺ (100)	901.2642 C ₃₉ H ₄₈ NO ₂₁ Cl ⁻ ; 866.2718 C ₃₉ H ₄₈ NO ₂₁ ⁻ (100), 753.2240 C ₃₄ H ₄₁ O ₁₉ ⁻ (45), 607.1660 C ₂₈ H ₃₁ O ₁₅ ⁻ (2), 461.1080 C ₂₂ H ₂₁ O ₁₁ ⁻ (16), 299.4627 C ₁₆ H ₁₁ O ₆ ⁻ (10)	0.17 ± 0.02
Quercetin-3- <i>O</i> - α -L-rhamnopyranosyl-(1 \rightarrow 2)-[6- <i>O</i> -(3-hydroxy-3-methylglutaryl)- β -D-galactopyranoside (QueHMG)	5.79 ± 0.010	754.1956; C ₃₃ H ₃₈ O ₂₀	755.2020 C ₃₃ H ₃₉ O ₂₀ ⁺ ; 611.1593 C ₂₇ H ₃₁ O ₁₆ ⁺ (49), 465.1027 C ₂₁ H ₂₁ O ₁₂ ⁺ (2), 303.0494 C ₁₅ H ₁₁ O ₇ ⁺ (100), 153.0181 C ₇ H ₅ O ₄ ⁺ (3)	753.1893 C ₃₃ H ₃₇ O ₂₀ ⁻ ; 609.1462 C ₂₇ H ₂₈ O ₁₆ ⁻ (15), 463.0910 C ₂₁ H ₁₉ O ₁₂ ⁻ (1), 301.0347 C ₁₅ H ₉ O ₇ ⁻ (22), 300.0277 C ₁₅ H ₈ O ₇ ⁻ (100), 151.0024 C ₇ H ₅ O ₄ ⁻ (4)	0.18 ± 0.02
Kaempferol-3- <i>O</i> - α -L-rhamnopyranosyl-(1 \rightarrow 2)-[6- <i>O</i> -(3-hydroxy-3-methylglutaryl)- β -D-galactopyranoside (KaeHMG)	6.21 ± 0.010	738.2007; C ₃₃ H ₃₈ O ₁₉	739.2072 C ₃₃ H ₃₉ O ₁₉ ⁺ ; 595.1538 C ₂₇ H ₃₁ O ₁₅ ⁺ (8), 449.1078 C ₂₁ H ₂₁ O ₁₁ ⁺ (1), 287.0545 C ₁₅ H ₁₁ O ₆ ⁺ (100), 153.0180 C ₇ H ₅ O ₄ ⁺ (6)	737.1942 C ₃₃ H ₃₇ O ₁₉ ⁻ ; 593.1515 C ₂₇ H ₂₉ O ₁₅ ⁻ (12), 447.0917 C ₂₁ H ₁₉ O ₁₁ ⁻ (1), 284.0327 C ₁₅ H ₉ O ₆ ⁻ (100), 285.0398 C ₁₅ H ₉ O ₆ ⁻ (29), 151.0031 C ₇ H ₅ O ₄ ⁻ (3)	0.17 ± 0.02
Kaempferol-3- <i>O</i> -[2- <i>O</i> - β -D-galactopyranosyl-6- <i>O</i> - α -L-rhamnopyranosyl]- β -D-glucopyranoside (camelliaside A, CamA)	4.99 ± 0.010	756.2112; C ₃₃ H ₄₀ O ₂₀	757.2191 C ₃₃ H ₄₁ O ₂₀ ⁺ ; 611.1625 C ₂₇ H ₃₁ O ₁₆ ⁺ (3), 449.1091 C ₂₁ H ₂₁ O ₁₁ ⁺ (5), 287.0551 C ₁₅ H ₁₁ O ₆ ⁺ (100), 153.0184 C ₇ H ₅ O ₄ ⁺ (2)	755.2035 C ₃₃ H ₃₉ O ₂₀ ⁻ ; 609.1450 C ₂₇ H ₂₉ O ₁₆ ⁻ (4), 447.0919 C ₂₁ H ₁₉ O ₁₁ ⁻ (3), 284.0328 C ₁₅ H ₉ O ₆ ⁻ (100), 285.0399 C ₁₅ H ₉ O ₆ ⁻ (47), 151.0026 C ₇ H ₅ O ₄ ⁻ (1)	0.19 ± 0.01
Quercetin-3- <i>O</i> - α -L-rhamnopyranosyl-(1 \rightarrow 2)-[α -L-rhamnopyranosyl-(1 \rightarrow 6)]- β -D-galactopyranoside (alcesefoliside, Alce)	4.94 ± 0.010	756.2114; C ₃₃ H ₄₀ O ₂₀	757.2191 C ₃₃ H ₄₁ O ₂₀ ⁺ ; 611.1604 C ₂₇ H ₃₁ O ₁₆ ⁺ (27), 465.1023 C ₂₁ H ₂₁ O ₁₂ ⁺ (13), 303.0499 C ₁₅ H ₁₁ O ₇ ⁺ (100), 153.0179 C ₇ H ₅ O ₄ ⁺ (1)	755.2045 C ₃₃ H ₃₉ O ₂₀ ⁻ ; 609.1480 C ₂₇ H ₂₉ O ₁₆ ⁻ (2), 463.0880 C ₂₁ H ₁₉ O ₁₂ ⁻ (1), 300.0279 C ₁₅ H ₉ O ₇ ⁻ (100), 301.0328 C ₁₅ H ₉ O ₇ ⁻ (13), 151.0030 C ₇ H ₅ O ₄ ⁻ (6)	0.16 ± 0.03
Kaempferol-3- <i>O</i> - α -L-rhamnopyranosyl-(1 \rightarrow 2)-[α -L-rhamnopyranosyl-(1 \rightarrow 6)]- β -D-galactopyranoside (mauritanin, Maur)	5.37 ± 0.020	740.2164; C ₃₃ H ₄₀ O ₁₉	741.2245 C ₃₃ H ₄₁ O ₁₉ ⁺ ; 595.1655 C ₂₇ H ₃₁ O ₁₅ ⁺ (30), 449.1073 C ₂₁ H ₂₁ O ₁₁ ⁺ (15), 287.0549 C ₁₅ H ₁₁ O ₆ ⁺ (100), 153.0182 C ₇ H ₅ O ₄ ⁺ (2)	739.2100 C ₃₃ H ₃₉ O ₁₉ ⁻ ; 593.1489 C ₂₇ H ₂₉ O ₁₅ ⁻ (2), 447.0929 C ₂₁ H ₁₉ O ₁₁ ⁻ (1), 284.0329 C ₁₅ H ₉ O ₆ ⁻ (100), 285.0393 C ₁₅ H ₉ O ₆ ⁻ (26), 151.0025 C ₇ H ₅ O ₄ ⁻ (4)	0.17 ± 0.03
Quercetin-3- <i>O</i> - α -L-rhamnopyranosyl-(1 \rightarrow 6)- β -D-glucopyranoside (Rutin)	5.69 ± 0.010	610.1533; C ₂₇ H ₃₀ O ₁₆	611.1605 C ₂₇ H ₃₁ O ₁₆ ⁺ ; 465.1026 C ₂₁ H ₂₁ O ₁₂ ⁺ (24), 303.0496 C ₁₅ H ₁₁ O ₇ ⁺ (100), 153.0180 C ₇ H ₅ O ₄ ⁺ (5)	609.1470 C ₂₇ H ₂₉ O ₁₆ ⁻ ; 463.0922 C ₂₁ H ₁₉ O ₁₂ ⁻ (1), 300.0280 C ₁₅ H ₉ O ₇ ⁻ (100), 301.0349 C ₁₅ H ₉ O ₇ ⁻ (48), 151.0028 C ₇ H ₅ O ₄ ⁻ (14),	0.14 ± 0.01
17(<i>R</i>),20(<i>R</i>)-3 β ,6 α ,16 β -trihydroxycycloartanyl-23-carboxylic acid 16-lactone 3- <i>O</i> - β -D-glucopyranoside (ECAS)	10.27 ± 0.010	578.3526; C ₃₂ H ₅₀ O ₉	579.3531 C ₃₂ H ₅₁ O ₉ ⁺ ; 417.3015 C ₂₆ H ₄₁ O ₄ ⁺ (100)	623.3438 C ₃₃ H ₅₁ O ₁₁ ⁻ ; 577.3381 C ₃₂ H ₄₉ O ₉ ⁻ (100), 415.3015 C ₂₆ H ₃₉ O ₄ ⁻ (56)	0.19 ± 0.01

*Fragment ions in MS² are in order of their *m/z*.

m/z 623.3438 (C₃₃H₅₁O₁₁⁻, formic acid present in the eluent system), therefore Fourier transformed Selected Ion Mode (FT-SIM) was used to detect this saponin.¹¹ In addition a FS as well as MS² chromatogram of each sample was recorded. An ion [M-H]⁻ was observed (*m/z* 577.3381 C₃₂H₄₉O₉⁻), as well as a fragment ion (*m/z* 415.3015, C₂₆H₃₉O₄⁻), corresponding to the sapogenin. The compound protonated to a small extent under positive ionization to give the [M+H]⁺ ion (*m/z* 579.3531, C₃₂H₅₁O₉⁺). A fragment ion *m/z* 417.3015 C₂₆H₄₁O₄⁺ was observed corresponding again to the sapogenin (see Figure 3 and Table 2).

Identification of compounds in the samples

The difference in retention times of the standards (Table 2) and the compounds in the samples was less than 0.05 min (mean value of three injections) and considered acceptable.²⁵ The TIC-FS chromatograms of each sample are in Supplementary. **QueFA** was identified in extracts from *A. monspessulanus* subsp. *monspessulanus*, collected both from Devin (Sample 7) and from Slavianka (Sample 8). This finding corroborates the presence of this flavoalkaloid in the species (Table 3).⁵ No other of the species examined accumulated the




Figure 2. Fragmentation patterns of flavoalkaloids and flavonoids investigated; abbreviations are as in Table 2

flavoalkaloid. **KaeFA** was discovered in extracts from *A. onobrychis* var. *chlorocarpus* (Samples 10, 11 and 12) as well as in extract from the herbs of *A. glycyphylloides* (Sample 4). This is the first report of the kaempferol flavoalkaloid presence in species other than *A. monspessulanus* subsp. *monspessulanus*. Analysis of extracts from the latter (Samples 7 and 8, Table 3) confirmed its accumulation and coincides with previous reports.⁵

The presence of **QueHMG** and **KaeHMG** was confirmed in the sample of *A. monspessulanus* subsp. *illyricus* (Sample 9, Table 3) and

consistent with previous results.⁵ No other of the examined species accumulated **QueHMG** (Table 3), while for the first time **KaeHMG** was identified in the extract of *A. depressus* (Sample 3, Table 3).

Camelliaside A was discovered in samples of *A. glycyphylloides* (Sample 4, Table 3) and *A. onobrychis* var. *chlorocarpus* (Samples 10, 11 and 12, Table 3). Analysis of extracts of *A. glycyphylloides* confirmed its presence in the species with accordance to literature.¹¹ Alcesefolside was discovered in samples of *A. cicer* (Samples 1 and 2), *A. glycyphylloides* (Sample 4) and *A. onobrychis* var. *chlorocarpus* (Samples 10, 11 and

Table 3. Secondary metabolites* identified in the samples

Sample No.	Species	QueFA	KaeFA	QueHMG	KaeHMG	CamA	Alce	Maur	Rutin	ECAS
1	<i>A. cicer</i>	-	-	-	-	-	+	+	+	-
2	<i>A. cicer</i>	-	-	-	-	-	+	+	+	-
3	<i>A. depressus</i>	-	-	-	+	-	-	-	-	-
4	<i>A. glycyphylloides</i>	-	+	-	-	+	+	+	-	-
5	<i>A. glycyphyllos</i>	-	-	-	-	+	-	+	+	+
6	<i>A. glycyphyllos</i>	-	-	-	-	+	-	+	+	+
7	<i>A. monspessulanus</i> subsp. <i>monspessulanus</i>	+	+	-	-	-	+	+	+	-
8	<i>A. monspessulanus</i> subsp. <i>monspessulanus</i>	+	+	-	-	-	+	+	+	-
9	<i>A. monspessulanus</i> subsp. <i>illyricus</i>	-	-	+	+	-	+	+	+	-
10	<i>A. onobrychis</i> var. <i>chlorocarpus</i>	-	+	-	-	+	+	+	+	+
11	<i>A. onobrychis</i> var. <i>chlorocarpus</i>	-	+	-	-	+	+	+	+	+
12	<i>A. onobrychis</i> var. <i>chlorocarpus</i>	-	+	-	-	+	+	+	+	+
13	<i>A. ponticus</i>	-	-	-	-	-	-	+	+	-

*Abbreviations are as in Table 2.

ECAS $[M+H]^+$ m/z 579.35 ($C_{32}H_{51}O_9^+$); $[M-H]^-$ m/z 577.35 ($C_{32}H_{49}O_9^-$)




Figure 3. Fragmentation of ECAS; abbreviation is as in Table 2

12, Table 3). Analysis of the samples of *A. monspessulanus* (both subspecies, Samples 7, 8, 9, Table 3) confirmed the previously reported data.⁵ Mauritianin was identified in the aerial parts of *A. glycyphylloides* (Sample 4) and *A. onobrychis* var. *chlorocarpus* (Samples 10, 11, 12 of Table 3), in *A. cicer* (Samples 1 and 2 Table 3) and in *A. ponticus* (Sample 13, Table 3). The results of the analysis of both subspecies of *A. monspessulanus* (*monspessulanus*, Samples 7 and 8, and *illyricus*, Sample 9, Table 3) coincide with previous reports.¹³

The presence of the epoxycycloartane saponin in the two samples of *A. glycyphyllos* confirmed a previous report.¹¹ The ECAS was identified for the first time in all extracts of *A. onobrychis* var. *chlorocarpus* (Table 3).

CONCLUSIONS

A novel rapid UHPLC-HRESIMS method was applied to detect rare flavoalkaloids, acylated and highly glycosylated flavonoids as well as a cycloartane saponin in samples of Bulgarian *Astragalus* species. These results will serve as the basis for thorough phytochemical screening of all Bulgarian representatives of this genus.

ACKNOWLEDGEMENTS

This work was supported by the Bulgarian Ministry of Education and Science under the National Program for Research “Young Scientists and Postdoctoral Students”.

REFERENCES

1. Zarre, S.; Azani, N.; *Prog. Biol. Sci.* **2013**, *3*, 1.

- Podlech, D.; *Feddes Repertorium* **2008**, *119*, 310.
- Asyov, B.; Petrova, A.; Dimitrov, D.; Vasilev, R. *Conspectus of the Bulgarian vascular flora. Distribution maps and floristic elements*; Bulgarian Biodiversity Foundation: Sofia, 2012.
- Krasteva, I.; Shkondrov, A.; Ionkova, I.; Zdraveva, P.; *Phytochem. Rev.* **2016**, *15*, 567.
- Krasteva, I.; Bratkov, V.; Bucar, F.; Kunert, O.; Kollroser, M.; Kondeva-Burdina, M.; Ionkova, I.; *J. Nat. Prod.* **2015**, *78*, 2565.
- Khadem, S.; Marles, R. J.; *Molecules* **2011**, *17*, 191.
- Porter, E. A.; van den Bos, A. A.; Kite, G. C.; Veitch, N. C.; Simmonds, M. S. J.; *Phytochemistry* **2012**, *81*, 90.
- Semmar, N.; Fenet, B.; Gluchoff-Fiasson, K.; Hasan, A.; Jay, M.; *J. Nat. Prod.* **2002**, *65*, 576.
- Simeonova, R.; Bratkov, V. M.; Kondeva-Burdina, M.; Vitcheva, V.; Manov, V.; Krasteva, I.; *Redox Rep. Commun. Free Radic. Res.* **2015**, *20*, 145.
- Andersen, O. M.; Markham, K. R. *Flavonoids: chemistry, biochemistry and applications*; CRC press, 2005.
- Shkondrov, A.; Krasteva, I.; Bucar, F.; Kunert, O.; Kondeva-Burdina, M.; Ionkova, I.; *Nat. Prod. Res.* **2020**, *34*, 511.
- Krasteva, I.; Nikolov, S.; Kaloga, M.; Mayer, G.; *Zeitschrift fur Naturforsch. - Sect. B J. Chem. Sci.* **2006**, *61*, 1166.
- Shkondrov, A.; Krasteva, I.; Bucar, F.; Kunert, O.; Kondeva-Burdina, M.; Ionkova, I.; *Phytochem. Lett.* **2018**, *26*, 44.
- Chaudhary, L. B.; Rana, T. S.; Anand, K. K.; *Taiwania* **2008**, *53*, 338.
- Uekane, T. M.; Aquino Neto, F. R.; Gomes, L. N. F.; *Quim. Nova* **2011**, *34*, 43.
- International conference on harmonization, Geneva, Switzerland, Guideline*, 2005, pp. 11.
- Bratkov, V.; Shkondrov, A.; Zdraveva, P.; Krasteva, I.; *Pharmacogn. Rev.* **2016**, *10*, 11.
- Maamria, L.; Haba, H.; Lavaud, C.; Harakat, D.; Benkhaled, M.; *J. Serbian Chem. Soc.* **2015**, *80*, 137.
- Benbassat, N.; Nikolov, S.; *Planta Med.* **1995**, *61*, 100.
- Fabre, N.; Rustan, I.; de Hoffmann, E.; Quetin-Leclercq, J.; *J. Am. Soc. Mass Spectrom.* **2001**, *12*, 707.
- Alves, C. Q.; David, J. M.; David, J. P.; Villareal, C. F.; Soares, M. B. P.; Queiroz, L. P. de; Aguiar, R. M.; *Quim. Nova* **2012**, *35*, 1137.
- Demarq, D. P.; Crotti, A. E. M.; Vessecchi, R.; Lopes, J. L. C.; Lopes, N. P.; *Nat. Prod. Rep.* **2016**, *33*, 432.
- Ablajan, K.; Tuoheti, A.; *Rapid Commun. Mass Spectrom.* **2013**, *27*, 451.
- Farias, L. da S.; Mendez, A. S. L.; *Quim. Nova* **2014**, *37*, 483.
- Swartz, M. E.; Krull, I. S.; *Analytical method development and validation*; CRC Press: Boca Raton, 2018.